INMUNE BIO INC. Increase (Decrease) in Income Taxes Receivable
INMUNE BIO INC. (INMB) reported Increase (Decrease) in Income Taxes Receivable of $20.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2024-05-09
- INMUNE BIO INC. increase (decrease) in income taxes receivable for the quarter ending 2024-03-31 was $20.00K, a 41.18% decline year-over-year.
- INMUNE BIO INC. increase (decrease) in income taxes receivable for the quarter ending 2023-03-31 was $34.00K.
- INMUNE BIO INC. increase (decrease) in income taxes receivable for the quarter ending 2021-12-31 was -$45.00K, a 120.36% decline year-over-year.
- INMUNE BIO INC. increase (decrease) in income taxes receivable for the quarter ending 2021-09-30 was $1.89M, a 350.00% increase year-over-year.
- INMUNE BIO INC. increase (decrease) in income taxes receivable for fiscal 2023 was $175.00K.
- INMUNE BIO INC. increase (decrease) in income taxes receivable for fiscal 2022 was -$229.00K, a 107.10% decline from fiscal 2021.
- INMUNE BIO INC. increase (decrease) in income taxes receivable for fiscal 2021 was $3.23M, a 188.64% increase from fiscal 2020.
- INMUNE BIO INC. increase (decrease) in income taxes receivable for fiscal 2020 was $1.12M.
| Period end | Increase (Decrease) in Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Receivable 3 month as first filed | Increase (Decrease) in Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Receivable 6 month as first filed | Increase (Decrease) in Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Receivable 9 month as first filed | Increase (Decrease) in Income Taxes Receivable 12 month | Increase (Decrease) in Income Taxes Receivable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | $20.00K 10-Q · filed 2024-05-09 | |||||||
| 2023-12-31 | $175.00K 10-K · filed 2024-03-28 | |||||||
| 2023-03-31 | $34.00K 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | -$229.00K 10-K · filed 2024-03-28 | |||||||
| 2021-12-31 | -$45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $1.84M derived: sum of 2 quarters · filed 2022-03-03 | $2.72M derived: sum of 3 quarters · filed 2022-03-03 | $3.23M 10-K · filed 2022-03-03 | ||||
| 2021-09-30 | $1.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $2.77M derived: sum of 2 quarters · filed 2021-11-03 | $3.27M 10-Q · filed 2021-11-03 | $3.49M derived: sum of 4 quarters · filed 2022-03-03 | ||||
| 2021-06-30 | $878.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $1.38M 10-Q · filed 2021-08-04 | $1.60M derived: sum of 3 quarters · filed 2022-03-03 | $2.02M derived: sum of 4 quarters · filed 2022-03-03 | ||||
| 2021-03-31 | $504.00K 10-Q · filed 2021-05-05 | $725.00K derived: sum of 2 quarters · filed 2022-03-03 | $1.15M derived: sum of 3 quarters · filed 2022-03-03 | $1.48M derived: sum of 4 quarters · filed 2022-03-03 | ||||
| 2020-12-31 | $221.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $641.00K derived: sum of 2 quarters · filed 2022-03-03 | $973.00K derived: sum of 3 quarters · filed 2022-03-03 | $1.12M 10-K · filed 2022-03-03 | $1.12M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $420.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $752.00K derived: sum of 2 quarters · filed 2021-11-03 | $897.00K 10-Q · filed 2021-11-03 | $897.24K 10-Q · filed 2020-11-05 | $511.15K derived: sum of 4 quarters · filed 2021-11-03 | |||
| 2020-06-30 | $332.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $477.00K 10-Q · filed 2021-08-04 | $476.70K 10-Q · filed 2020-08-05 | $91.16K derived: sum of 3 quarters · filed 2021-08-04 | $201.45K derived: sum of 4 quarters · filed 2021-08-04 | |||
| 2020-03-31 | $145.00K 10-Q · filed 2021-05-05 | $144.98K 10-Q · filed 2020-05-14 | -$240.84K derived: sum of 2 quarters · filed 2021-05-05 | -$130.55K derived: sum of 3 quarters · filed 2021-05-05 | $107.41K derived: sum of 4 quarters · filed 2021-05-05 | |||
| 2019-12-31 | -$385.85K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$275.55K derived: sum of 2 quarters · filed 2021-03-04 | -$37.59K derived: sum of 3 quarters · filed 2021-03-04 | -$24.08K 10-K · filed 2021-03-04 | ||||
| 2019-09-30 | $110.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $348.25K derived: sum of 2 quarters · filed 2020-11-05 | $361.77K 10-Q · filed 2020-11-05 | $629.48K derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $237.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $251.47K 10-Q · filed 2020-08-05 | $519.19K derived: sum of 3 quarters · filed 2020-08-05 | $581.00K derived: sum of 4 quarters · filed 2020-08-05 | ||||
| 2019-03-31 | $13.52K 10-Q · filed 2020-05-14 | $281.23K derived: sum of 2 quarters · filed 2020-05-14 | $343.05K derived: sum of 3 quarters · filed 2020-05-14 | $444.07K derived: sum of 4 quarters · filed 2020-05-14 | ||||
| 2018-12-31 | $267.71K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $329.53K derived: sum of 2 quarters · filed 2020-03-11 | $430.55K derived: sum of 3 quarters · filed 2020-03-11 | $485.35K 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | $61.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $162.84K derived: sum of 2 quarters · filed 2019-11-08 | $217.63K 10-Q · filed 2019-11-08 | |||||
| 2018-06-30 | $101.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $155.82K 10-Q · filed 2019-08-09 | ||||||
| 2018-03-31 | $54.80K 10-Q · filed 2019-05-15 | |||||||
| 2017-12-31 | $38.00K 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |